$JNJ mention timeline

Johnson & Johnson. Every tracked FinTwit mention of $JNJ, newest first. 48 mentions since the first on Jun 16, 2025. See the price chart.

June 2026 · 1 mention

Jun 1
Jacob Plieth — $RVMD $SMMT $BNTX $AZN $MRK $BMY $LLY $IDYA $JNJ $GILD $INCY $PFE $NVS $AVBP #Asco26↗

May 31
Adam Feuerstein ✡️ — Happy Sunday morning, my friends. If you're an #ASCO26 follower, the media embargoes lift at 8 am ET for daraxonrasib, ivonescimab and all the other drugs in this afternoon's plena…↗
May 29
Jacob Plieth — Dizal Zegfrovy data from WU-Kong28, in NEJM https://t.co/qx2TwwHq7g #ASCO26 $CGEM $JNJ↗
May 29
Jacob Plieth — Dizal: crossover ate my OS benefit. #ASCO26 data from WU-Kong28 in 1st-line exon20 NSCLC, via @ApexOnco -> https://t.co/8fzt66W6eo $JNJ $CGEM↗
May 20
Adam Feuerstein ✡️ — The #ASCO26 abstracts will be posted tomorrow at 5 pm EDT. What this means, and what is doesn't. -- No late-breaker abstracts tomorrow. You will not see the plenary session data…↗

Apr 17
Jacob Plieth — Second $JNJ ex-Halda "riptac", HLD-0117, goes into phase 1. Previously only known as "breast cancer riptac", target still undisclosed https://t.co/aJRe55AgYH↗
Apr 17
Jacob Plieth — "Extended-release chemotherapy"? $JNJ 🧐 https://t.co/YNyf9f6GP1↗

Mar 18
Adam Feuerstein ✡️ — J&J $JNJ wins approval for first-of-its-kind psoriasis pill https://t.co/i3nkTz8mi1 via @damiangarde $PTGX↗
Mar 16
Jacob Plieth — Who knew $REGN was developing an anti-GPRC5D T-cell engager? https://t.co/jyL1PAS0y5 $JNJ $PFE $BMY↗
Mar 5
Adam Feuerstein ✡️ — FDA approved $JNJ Tecvayli, multiple myeloma treatment https://t.co/7JX80XjYy9↗

Feb 23
Jacob Plieth — Why is $BCAX testing a ficera dose in phase 3 that it now says isn't optimal (and other uncomfortable questions)? Via @ApexOnco -> https://t.co/mLWKP6AAZ9 $JNJ $GMAB↗
Feb 23
Jacob Plieth — $GILD buys $ACLX before approval. Via @ApexOnco -> https://t.co/pKF78Wyrww $LEGN $JNJ↗

Jan 29
Jacob Plieth — MK-2750 has been in the clinic since 2024. JNJ-95437446 started phase 1 in July 2025 https://t.co/PYUnhSJogA $MRK $JNJ↗
Jan 29
Jacob Plieth — With a tipoff from a friend, and some info that probably shouldn't have been posted in a trial registry, the mechanisms of ADCs JNJ-95437446 $JNJ & SKB571/ MK-2750 $MRK have be…↗
Jan 15
Jacob Plieth — Qilu appears to be aping $JNJ in trispecific T-cell engagers. First BCMA x GPRC5D, now CD79b x CD20. Via @ApexOnco -> https://t.co/d4pBcl0MuF↗
Jan 14
Adam Feuerstein ✡️ — @SweetStocks22 @DrPatrick The glioblastoma data (scant) come from single arm combination trials. None of the data prove Anktiva is having any effect at all. And yes, Anktiva is a…

Dec 23
KawzInvests 🦑 — Then you layer in the competitive dynamics. The article explicitly says $LLY is negotiating but $JNJ and AstraZeneca $AZN are also monitoring the situation. When you have three maj…↗
Dec 15
Jacob Plieth — It's $JNJ Tecvayli https://t.co/83ezqcZxm8↗
Dec 9
Jacob Plieth — If you enjoyed #ASH25 you can catch up on all @ApexOnco coverage, including previews, here -> https://t.co/XIQrEeKMwY $TERN $JNJ $LLY $CGEM $ONC $NRIX $PFE $REGN $KURA↗
Dec 9
Jacob Plieth — @avidresearch OS, even with slightly fugly crossover, gives HR=0.46 $JNJ #ASH25 As ever, infection risk is very real with CD3-targeting T-cell engagers.

Nov 25
Adam Feuerstein ✡️ — @bigpharmaguy Not insane. You're correct. The competitive hit to $ACLX y'day was present (that $JNJ abstract) and future (the in vivo CAR-T) I didn't see the former until later.↗
Nov 24
Jacob Plieth — #ASH25 late-breakers are now up (links don't work though): $JNJ $LLY + Kelonia in vivo Car-T! https://t.co/O9NqyOuXya↗
Nov 17
Jacob Plieth — Halda turns $202m into $3bn from $JNJ (plus a #sadtrombone for $ARVN). Via @ApexOnco -> https://t.co/7zXwDOTMS6↗
Nov 17
Jacob Plieth — Who knew?! $ARVN $JNJ

Sep 17
Jacob Plieth — Amazing similarities (& differences?) between Flaura2 vs Mariposa $AZN $JNJ↗
Sep 11
Jacob Plieth — Here's another oncology company going from ph1 straight into ph3: $JNJ anti-KLK2 T-cell engager pasritamig https://t.co/KpW7G2wNs0 cc @BowTiedBiotech↗
Sep 8
Jacob Plieth — If you're catching up with #WCLC25 news, @ApexOnco coverage can be found here: https://t.co/Jl2xGAtcZw $SMMY $IDYA $AZN $JNJ $BMY $ZLAB $BNTX↗
Sep 8
Jacob Plieth — Guess who just went into the clinic with a new menin inhibitor $SNDX $KURA $JNJ $AZN https://t.co/J1NxKIddpD

Aug 27
Nancy Pelosi Stock Tracker ♟ — The plan ? See if the Swift Effect can make you rich A new tracker is now live up on @joinautopilot and is a basket of stocks that would benefit from a "marriage boom" Includes…↗

Jul 17
Jacob Plieth — ...and more, this time from the FDA's Andrea Baines $BMY $JNJ $GSK $LEGN https://t.co/8UEG4QyKPq↗
Jul 17
Jacob Plieth — $JNJ first announced TAR-200 filing on 15 Jan, but never announced the acceptance. Today's PR likely result of mention of priority review dribbled out at GS conf in June & on y…↗
Jul 17
Jacob Plieth — Admirable effort by FDA's Deepti Telajara to present the current treatment paradigm for multiple myeloma $JNJ $BMY $GSK https://t.co/VfdzITcqRY↗
Jul 11
Jacob Plieth — Huh?! $JNJ $LEGN $BMY

Jun 16
Jacob Plieth — @justaname2u JNJ-88549968 appears to be the only other CALRmut project in clinical development apart from the two at $INCY. Ph1 started in Dec 2023, but has anyone seen any data fr…↗
Jun 1
Jacob Plieth — $JNJ anti-KLK2 T-cell engager pasritamig (JNJ-78278343) #ASCO25↗